Welcome to our comprehensive ‘Resources’ section at Miller’s Pharmacy, where we provide a wealth of information and tools designed to support and empower your healthcare journey. Understanding and managing your medication has never been easier with our intuitive Medication Lookup Tool, offering detailed insights into various drugs, their uses, and potential side effects. For your convenience, we’ve also compiled an array of essential Medical Document Downloads, providing easy access to forms and information crucial for your health management. Additionally, stay informed with our live FDA Drug Alert Feed, a valuable resource that keeps you updated on the latest drug safety news and alerts directly from the FDA. This page is tailored to enhance your healthcare experience by providing easy access to important information and resources, ensuring you have everything you need for informed health decisions right at your fingertips.
Pharmacy Resources
Downloads
EUA COVID-19 Vaccine Fact Sheet for
Recipients and Caregivers
FDA Drug Alerts
- Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
- VitalityVita Issues Voluntary Nationwide Recall of VitalityXtra and PeakMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac
- Boulla LLC Issues Voluntary Nationwide Recall of ZoomMax and ZapMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac
- FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness
- Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health
- Public Safety Notification on Amniotic Fluid Eyedrops
- C&A Naturistics Issues Voluntary Nationwide Recall of AK Forte Tablets con Ortiga y Omega 3 Due to the Presence of Undeclared Drug Ingredients
- Staska Pharmaceuticals, Inc. Issues Recall of Ascorbic Acid Solution for Injection (Preservative Free, Non-Corn) 500mg/mL Due to the Presence of Glass Particles
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
- FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns